Context: Members of the insulin-like growth factor (IGF) system are primarily produced in the liver and secreted into the circulation, but they are also produced, recruited, and activated locally in tissues.
T he components of the circulating insulin-like growth factor (IGF) system are primarily synthesized in the liver under the control of growth hormone (GH) and insulin. However, many IGF-related proteins are also produced locally within the tissue and detectable in tissue fluids (1) (2) (3) .
The primary target of the IGF system is the IGF-1 receptor (IGF-1R), which activates mitogenic, metabolic, and antiapoptotic pathways (4) . IGF-1 is the most important ligand of the IGF-1R, whereas activation by IGF-2 appears less potent (5) . The ability of the IGFs to activate the IGF-1R is controlled by six high-affinity IGFbinding proteins (IGFBPs; IGFBP-1 to -6). The IGFBPs act as IGF carriers, prolonging their circulating half-life and limiting interaction between the IGFs and the IGF-1R (4) . Consequently, liberation of IGF from the IGFBPs constitutes a key regulatory point.
Bound IGF is released by IGFBP-specific and unspecific proteinases; this, by cleavage, reduces the ligand affinity of the IGFBPs, thereby liberating IGF (6, 7) . The physiological role of IGFBP proteinases remains to be fully clarified, but studies of pregnancy-associated plasma protein-A (PAPP-A) and PAPP-A2, which target individual IGFBPs, suggest these proteinases do regulate IGF actions in vivo (7) (8) (9) . Experimental studies document that PAPP-A modulates IGF-1 mediated growth (7, 8) and recent findings suggest PAPP-A2 possesses similar effects in mice (10) and humans (11) .
IGFBP proteinases are ubiquitous but believed to be most active in tissues and extravascular fluids (12) (13) (14) , supposedly serving to release bound IGF near the IGF-1R. In this context, we have previously demonstrated that both nonpathological and pathological extravascular fluids, despite containing lower IGF concentrations than serum, possess an increased ability to activate the IGF-1R in vitro. Furthermore, extravascular fluids also contained increased IGFBP fragment levels (15) (16) (17) and PAPP-A (16) , supporting the notion that within tissues, proteinases increase IGF-1R activation by IGFBP cleavage and subsequent liberation of IGF.
The factors that control proteinase activity are far from clear, but inflammation is likely to play a key role. The expression of PAPP-A is upregulated by cytokines (3) and elevated in pathological ascites (16) , which is likely to be inflamed. In contrast, the extravascular proteolysis of IGFBP-3 appears to be inhibited by inflammation and normalized by glucocorticoid administration (13) . Thus, different inflammatory responses may have distinct effects on the IGF system.
The aim of this study was to describe the activity and composition of the IGF system in pathological pleural fluid and serum from patients who accumulated pleural fluid due to malignant or nonmalignant pulmonary or pleural diseases. We have previously shown PAPP-A to be highly elevated in pathological ascites; therefore, we paid particular attention to this proteinase and its interaction with stanniocalcin-2 (STC2), a newly discovered PAPP-A inhibitor (18) . In addition, we focused on IGFBP-4, which is the primary target of PAPP-A (7, 8) , and levels of free and bioactive IGF.
Subjects and Methods

Study participant recruitment
Patients with pathological pleural fluid were enrolled after referral to the Department of Pulmonary Medicine at Aarhus University Hospital under the suspicion of lung cancer because of abnormal radiograph or computed tomography scan of the chest. Blood samples were collected, centrifuged, separated in aliquots, and stored at 280°C together with pleural fluid, which was collected by puncture as part of the diagnostic and therapeutic workup. Exclusion criteria were previous malignancies apart from nonmelanoma skin cancer, severe heart failure (New York Heart Association class III/IV), hemoglobin A1c .7.0% Diabetes Control and Complications Trial units (53 mmol/mol) and an estimated glomerular filtration rate ,40 mL/min.
Written informed consent was obtained from all participants. The study was approved by the local ethics committee on medical research (Approval no. 1-10-72-155-12) and conducted in accordance with the Declaration of Helsinki.
Patient characteristics
Pleural fluids and matching serum/plasma samples were collected from 24 patients (13 men and 11 women). The mean age of the patients was 75 years (range, 66.7 to 81.9) and the mean body mass index was 23.5 kg/m 2 (20.9 to 24.8 kg/m 2 ). Nine patients were diagnosed with primary lung cancer (non-small cell lung cancer, n = 7; or small cell lung cancer, n = 2) and four patients had lung metastases from other malignancies (i.e., mesothelioma, sarcoma, prostate cancer, and pleural metastasis). Eleven patients had a nonmalignant disease resulting in pleural effusion (e.g., pneumonia). Seven patients were active smokers, 14 were ex-smokers, one was a never-smoker, and for two subjects, no smoking information was available.
Assays
All assays were performed in pleural fluid and in serum/ plasma. Care was taken to assay paired samples within the same assay run.
IGF-1, IGF-2, and pro-IGF-2
Serum IGF-1, IGF-2, and pro-IGF-2 were determined after dissociation from IGFBPs at low pH, using gel chromatography, as recently detailed (19) . IGFBP-free fractions were analyzed by in-house, time-resolved immunofluorometric assays (TR-IFMAs) (19) . Intra-and interassay coefficients of variation (CVs) were ,4% and ,13%, respectively. The IGF-1 assay was calibrated against the World Health Organization (WHO) 02/254 standard and the IGF-2 assay against the WHO 96/538 standard (National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom). The pro-IGF-2 assay was calibrated against rh-pro-IGF-II (Gropep Bioreagents, Adelaide, SA, Australia).
Free IGF-1 and -2 by ultrafiltration
Free, unbound IGF-1 and IGF-2 were determined using ultrafiltration, performed at 37°C, as described (20) .
IGFBP-2 and -3
IGFBP-2 was measured using an in-house time-resolve immunofluorometric assay (TR-IFMA) as described, with intra-and interassay CVs of 5% and 12%, respectively (21) . Serum IGFBP-3 was determined using the IDS-iSYS platform (Immunodiagnostic Systems, Copenhagen, Denmark), as described (22) .
IGFBP-2 and -3 fragments
IGFBP-2 and -3 were analyzed in serum and pleural fluid by Western immunoblotting under reducing or nonreducing conditions. Polyvinylidene difluoride membranes were incubated with goat anti-human IGFBP-2 antibody (1:1000; catalog no. sc-6002; Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit anti-human IGFBP-3 (1:600; catalog no. 13216; Cell Signaling Technology, Danvers, MA) in Tris-buffered saline, 0.05% Tween20, and 3% skimmed milk for 2 hours at room temperature or overnight at 4°C, followed by a 1-hour incubation with horseradish peroxidase-conjugated anti-goat immunoglobulin G (1:2500; catalog no. sc-2020; Santa Cruz Biotechnology) or anti-rabbit immunoglobulin G (1:2500; catalog no. 7074S; Cell Signaling Technology). Proteins were detected on a ChemiDoc MP System (Bio-Rad, Hercules, CA) by enhanced chemiluminescence using the reagent Luminata Forte (Merck Millipore, Darmstadt, Germany). Signal intensities of intact IGFBP and its fragments were quantified using the Gelanalyzer2010a software. As positive controls, rh-IGFBP-2 and -3 (R&D Systems, Wiesbaden, Germany) were used. Molecular mass of target proteins was determined using the prestained protein marker Broad Range (catalog no. 14208; Cell Signaling Technology). As an indicator for proteolysis, the ratio of fragments to intact IGFBPs was calculated for each sample.
IGFBP-4 and IGFBP-4 fragments
IGFBP-4 and the two fragments specifically generated by PAPP-A-mediated cleavage of IGFBP-4 (i.e., C-terminal-IGFBP-4 and N-terminal-IGFBP-4) were measured using in-house TR-IFMAs based on monoclonal antibodies and recombinant human calibrators generously provided by HyTest (Turku, Finland). The assays were performed as described (23) . Intra-and interassay CVs were ,10% and ,15%, respectively.
PAPP-A, PAPP-A2, and STC2
PAPP-A and PAPP-A2 were determined using commercial sandwich enzyme-linked immunoassays generously provided by AnshLabs (Webster, Texas). STC2 was measured by inhouse TR-IFMA, as described (18) .
Bioactive IGF by kinase receptor activation assay
The potential of serum and pleural fluid, respectively, to activate the IGF-1R in vitro (i.e., IGF bioactivity) was measured by an in-house kinase receptor activation assay, as detailed (5, 21) . Briefly, the assay measures in vitro IGF-1R activation using human embryonic kidney cells transfected with cDNA of the human IGF-1R gene. The level of phosphorylation in samples was compared with that of a serial dilution of rh-IGF-1 (WHO 02/254). This assay also detects IGF-2 and pro-IGF-2 activation of the IGF-1R (cross-reactivity 12% and 2%, respectively), whereas the cross-reactivity of proinsulin and insulin is negligible (,1%). Thus, assay output is referred to as IGF bioactivity because both IGF-1 and IGF-2 can activate the IGF-1R. The detection limit of this assay is ,0.1 mg/L. Intraand interassay CVs averaged 12% and 20%, respectively.
Cytokines and inflammatory markers
Cytokine levels [interleukin (IL)-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17A, interferon-g, and tumor necrosis factor (TNF)-a] were measured by a magnetic BioPlex Pro kit (Bio-Rad) according to instructions. Responses were analyzed using the BioPlex Manager 6.0 software (Bio-Rad). IL-9 and IL-17A levels were below the detection limit in most patients and thus not reported. Serum C-reactive protein was determined by in-house TR-IFMA based on commercially available monoclonal antibodies (MAB17071 and BAM17072; R&D Systems), and calibrated against WHO 85/506 (National Institute for Biological Standards and Control). Intra-and interassay CVs were ,5% and ,6%, respectively.
Statistics
In quantile-quantile plots, all variables approximated the normal distribution upon logarithmic transformation. Data are reported as median and interquartile range [i.e., median (25th percentile; 75th percentile)]. Groups were compared with Student t test, assuming equal or unequal variance as appropriate. Statistics and figures were produced with Stata statistical software, release 12 (StataCorp, College Station, TX). P values #0.05 were considered statistically significant.
Results
IGF concentrations and bioactivity in pleural fluid vs circulation
All analyzed components of the IGF system were detectable in pleural fluid and serum/plasma (Table 1 ; Fig. 1 ). Data were similar regardless of etiology and, consequently, all patients were analyzed as one group. Pleural fluid contained similar IGF-1 concentrations, but lower IGF-2 concentrations, as compared with serum (P , 0.0001). Despite this, the in vitro IGF bioactivity of pleural fluid was 3.4-fold higher than that of serum (P , 0.0001). This finding was in agreement with concentrations of free IGF-1, which were 3.2-fold higher in pleural fluid than serum (P , 0.0001), whereas free IGF-2 showed an opposite change, being marginally, but significantly, higher in serum than pleural fluid (P , 0.0005).
IGFBP-4, PAPP-A, and STC2 in pleural fluid vs circulation
The concentration of PAPP-A was highly elevated in all pleural fluids, being, on average, 47-fold higher than in serum (P , 0.0001). This may explain why concentrations of intact IGFBP-4 in pleural fluid were markedly reduced, whereas levels of the two PAPP-A-generated IGFBP-4 fragments were elevated in pleural fluid as compared with plasma (P , 0.0005). STC2 levels were of similar magnitude in pleural fluid and serum (Table 1) . In pleural fluid, we observed a positive correlation between levels of intact IGFBP-4 and STC2 (r = 0.53; P = 0.01), whereas levels of the two PAPP-A-generated IGFBP-4 fragments correlated inversely with STC2 (r # 20.42; P # 0.05; Fig. 2 ). In plasma, no correlations between STC2 and IGFBP-4 or its fragments were observed.
IGFBP-2, IGFBP-3, and PAPP-A2
Neither IGFBP-2 concentration nor the degree of IGFBP-2 fragmentation as estimated by Western blotting (22-to 25-kDa IGFBP-2 fragment) differed between compartments. In contrast, both IGFBP-3 concentration and fragmentation, evaluated by Western blotting, were significantly higher in serum than pleural fluid (Table 1) . Finally, levels of PAPP-A2 were increased 3.3-fold in pleural fluid as compared with serum (P = 0.003). PAPP-A2 correlated with STC2 in serum (r = 0.50; P = 0.04), but not in pleural fluid.
Inflammatory proteins in pleural fluid vs circulation
In pleural fluid, median levels of IL-6 showed a 143-fold increase as compared with plasma. A positive correlation between IL-6 and PAPP-A concentrations was found in pleura (r = 0.46; P = 0.02; Fig. 2 ), but not in plasma. No correlations between PAPP-A2 and IL-6 were observed.
Apart from IL-6, the levels of the other cytokines investigated (i.e., IL-2, IL-4, IL-5, IL-10, IL-12, interferon-g, and TNF-a) were either significantly lower in pleural fluid when compared with matched plasma samples or found in equal concentrations (IL-1b, IL-13; Table 2 ; Fig. 3 ).
The IGF system and inflammatory proteins in patients with cancer vs patients without cancer Irrespective of compartment, only minor differences were observed when comparing patients diagnosed with (n = 13) and without (n = 11) cancer-related lung disease. Median IGF-2 levels were higher in patients with cancer than in those without in both serum (490 vs 371 mg/L; P , 0.008) and pleural fluid (167 vs 111 mg/L; P = 0.003), and the same was true for the pleural fluid to serum ratio of IGF-2 (0.39 vs 0.30; P = 0.02; Fig. 4) . Additionally, IL-5 and IL-10 levels were increased in pleural fluids from Concentrations given as median (interquartile range).
Abbreviations: CRP, C-reactive protein; IFN-g, interferon gamma; nd, not detectable.
patients with cancer (Fig. 4) , who also showed an increased pleural fluid to plasma ratio for IL-5 (P = 0.02).
Discussion
In a recent study comparing serum and ascites from women with ovarian carcinoma, we demonstrated that ascites contained 46-fold higher concentrations of PAPP-A than serum (16) . Therefore, the current study was undertaken to investigate whether the same phenomenon could be observed in elderly patients with pathological pleural fluid. Indeed, this turned out to be the case. In all 24 subjects, pleural fluid contained higher concentrations of PAPP-A than serum. On average, PAPP-A levels were 47-fold higher in pleural fluid than serum, with no distinctions between patients with and without cancer. In addition, pleural fluid contained less intact IGFBP-4 (the primary target of PAPP-A) (8) , and more IGFBP-4 fragments. The concentration of IGF-1 was similar in pleural fluid and serum; nevertheless, pleural fluid contained 3.2-fold higher levels of free IGF-1 and 3.4-fold higher levels of bioactive IGF. Finally, our data suggested inflammation plays a key role in the observed changes. In all pleural fluids, IL-6 levels were highly elevated and correlated positively with those of PAPP-A. This study demonstrates highly elevated concentrations of PAPP-A in pathological pleural fluid. This supports the hypothesis that PAPP-A regulates IGF bioavailability in the local environment through cleavage of IGFBP-4, resulting in two specific IGFBP-4 fragments and liberation of IGF-1 (14, 24) . However, one must be careful to translate high PAPP-A concentrations into increased enzymatic activity (25) . Thus, it is well known that PAPP-A exists in both enzymatically active and inactive forms and that PAPP-A immunoassays, in general, are unable to make such discriminations (26, 27) . However, by using specific IGFBP-4 immunoassays, we demonstrated that, in pleural fluid, nearly all IGFBP-4 was enzymatically cleaved, because IGFBP-4 immunoreactivity predominantly originated from two IGFBP-4 fragments highly specific for PAPP-A (27) . In conjunction, this indicates that the elevated PAPP-A concentration in pleural fluid, in fact, did translate into increased enzymatic activity.
PAPP-A2 levels were also elevated in pleural fluid but relatively less than that of PAPP-A. The main difference between the two enzymes is their targets: PAPP-A primarily cleaves IGFBP-4 and -5 and, to some extent, IGFBP-2, whereas PAPP-A2 cleaves IGFBP-3 and -5 (7). Another difference is the lack of assays that specifically measure PAPP-A2-generated IGFBP fragments, which prevented us from estimating the endogenous PAPP-A2 activity. However, despite elevated PAPP-A2 levels in pleural fluid, the fragmentation of IGFBP-3, as estimated by Western blotting, was lower than that in serum. Thus, we speculate that PAPP-A2, in contrast to PAPP-A, was less active in pathological fluid. This hypothesis agrees with earlier findings (13) . Although these earlier studies did not identify the proteinase, the authors could show that, in the normal state, the degradation of IGFBP-3 was controlled by (yet unidentified) proteinase inhibitors that were restrained to within the circulation, allowing an opposed degradation of IGFBP-3 in the tissues. However, during inflammation, the capillary permeability increases, thereby allowing circulating IGFBP-3 proteinase inhibitors to infiltrate the extravascular compartment and, consequently, to inhibit IGFBP-3 degradation in inflamed tissues (13) . As judged from levels of interleukins, TNF-a, and C-reactive protein, inflammation was present in all pleural fluids, thereby potentially explaining that the proteolysis of IGFBP-3 was lower in the extravascular compartment than in serum. However, to study this further, the activity of PAPP-A2 needs to be investigated in noninflamed vs inflamed extravascular fluids.
The presence of elevated IGFBP-4 fragments and reduced IGFBP-3 fragments indicates that proteinases and proteinase regulators with opposing effects may be operative in pathological pleural fluid. The most recently discovered enzyme regulator is STC2, which, by forming covalent complexes with PAPP-A and PAPP-A2, inhibits their proteinase activity (18, 28) . Levels of STC2 were comparable in plasma and pleural fluid, but only in the latter compartment did STC2 show correlations with IGFBP-4 and its two fragments. Although correlative Figure 3 . Distribution of cytokines in extravascular fluid (pleural effusion) and circulation (blood). Ratios .1 and those ,1 reflect increased extravascular levels and increased levels in circulation, respectively. *Significant difference between compartments (P , 0.05). See Fig. 1 caption for explanation of boxes and whiskers.
findings are not proof of a causal association, they support experimental findings demonstrating that STC2, by inhibition of PAPP-A, downregulates IGFBP-4 proteolysis, thereby leaving IGFBP-4 in its intact form (7, 18) . However, this hypothesis cannot explain why similar correlations were not observed in the circulation. In plasma, a fraction of PAPP-A is enzymatically inactivated after complex formation with the proform of eosinophil major basic protein (8, 29) . Suppressed circulating PAPP-A activity may explain why plasma levels of intact IGFBP-4 exceeded those of the two PAPP-A generated fragments. Thus, we speculate that PAPP-A in plasma is already enzymatically suppressed to an extent that further suppression yields little effect, whereas in inflamed tissues, the invasion from the circulation of STC2 may have an impact. However, this hypothesis requires detailed investigations of the forms of PAPP-A and STC2 in different tissues, a topic that is beyond the scope of the current study.
Levels of free and bioactive IGF may yield an estimate of the activity of the IGF system in pleural fluid. Free IGF-1 and bioactive IGF were more than threefold elevated, despite similar concentrations of IGF-1 in pleural fluid and serum. This indicates that the ratio between IGF-1 and the intact highaffinity IGFBPs is changed in favor of IGF-1, and it is tempting to speculate that proteinases (e.g., PAPP-A) are involved in promoting IGF-1 action. However, our study does not allow us to make solid conclusions in this regard. Our study also showed that whereas pleural fluid IGF-1 concentrations were similar to those of serum, IGF-2 concentrations constituted only about one-third of their serum values. Because IGF-1 and IGF-2 are bound to the same IGFBPs, this finding is unlikely to originate from differences in the ability of circulating IGF-1 and IGF-2 to cross the capillary. Rather, it may relate to differences in the local degradation/clearance or synthesis of the two IGFs. The lower concentration of IGF-2 in pleural fluid may readily explain why free IGF-2 was not elevated to the same extent in pleural fluid as free IGF-1. Furthermore, this observation indicates that the increased ability of pleural fluid to activate the IGF-1R in vitro is caused by free IGF-1.
PAPP-A is reported to cleave IGFBP-2 in an IGFdependent fashion but with a 25-fold less efficient cleavage activity than for IGFBP-4 (30, 31) . Our study did not show any difference in IGFBP-2 cleavage between serum and pleural fluid, in contrast to IGFBP-4, which was almost completely fragmented in the latter compartment. This implies that IGFBP-2 was less affected by the highly elevated PAPP-A levels in pleural fluid. Proinflammatory cytokines such as TNF-a, IL-1b, and IL-6 are known to stimulate PAPP-A expression in cultured cells, whereas the regulators of PAPP-A2 remain unknown (8) . We found highly increased IL-6 levels in pleural fluid regardless of disease etiology. This indicates that IL-6 is produced locally at the site of active disease and may be the principal factor for PAPP-A regulation. IL-6 is a pleiotropic cytokine produced by various cells and it executes multiple biological activities, including immune regulation and stimulation of hepatic proteins and oncogenesis (32, 33) . On this basis, we hypothesize that the increase in PAPP-A levels are causatively linked to the increase in IL-6. In support of our findings, Alexandrakis et al. (34) reported a 14-to 23-fold increase in IL-6 levels in pleural fluid from patients with benign or malignant pleural effusion. Interestingly, no correlation was found between IL-6 and PAPP-A2 levels, which indicates a difference in the regulation of the two proteinases.
IGF-2 was the only IGF-related protein that differed between patients with and without cancer, levels being higher in both serum and pleural fluid, respectively, from patients with cancer. Additionally, IL-5 and IL-10 levels were higher in pleural fluid from patients diagnosed with cancer. The clinical significance of these observations remains unknown and groups were small, precluding firm conclusions. However, Makins and Ballinger (35) reported a 14% increased growth in a colon cancer cell line after coincubation with IGF-2 and IL-5 as compared with cells incubated with IGF-2 alone. Thus, the combination of elevated IGF-2 and IL-5 may potentially result in an unfavorable outcome, but this has to be further explored.
The current study has strengths and limitations. It is a strength that all IGF data were derived from matching pleural fluid and blood samples. However, the study also contains limitations. Foremost, the cross-sectional design of the study and the small number of patients prevented us from linking our observations to clinical outcomes. Another limitation is that the included patients were relatively old. Given the age dependence of GH and the IGF system (36, 37) , one should be cautious in extrapolating these findings to younger age groups. Similarly, one should be careful when extrapolating data based on the in vitro IGF bioactivity assay to the actual in vivo situation. Finally, it is important to stress that the data in this study were obtained in pathological pleural fluid and serum samples obtained from nonhealthy subjects. Some patients had relatively acute conditions such as pulmonary infection, others had cancer, and, given the body mass index of the patients, which was rather low for age, it appears likely that most patients had chronic illness (e.g., chronic obstructive pulmonary disease), because many were or had been smokers. These conditions are likely to affect our results. Another issue is the source of IGF-related peptides in pleural fluid. This study cannot determine whether they originated from the circulation, from an increased local production, or a combination of these. Local inflammation may alter the transport of proteins across the capillaries (13, 38) , and the presence of chronic disease may affect the production of IGFrelated proteins systemically and locally within the tissues, as well as the ability of GH to stimulate IGF-1 production (39) . Therefore, it is unwise to extrapolate these data to the situation in normal subjects.
In conclusion, this study demonstrates that in pathological pleural fluid, the composition of the IGF system is altered in favor of promoting free and bioactive IGF-1. Local acting proteinases (e.g., PAPP-A) and inflammatory proteins (e.g., IL-6) may play a central role in stimulating local IGF action, and the PAPP-A-inhibiting protein STC2 may also be involved. In conjunction, our study supports the hypothesis that local factors within the tissues may have a major effect on the activity of the IGF system, and that these changes cannot be detected by measurement of the circulating IGF system.
